无水焦磷酸钠

无水焦磷酸钠用途

【用途一】
用作印染精漂助剂、软水剂等
【用途二】
用作电镀液中铜的络合剂。机械加工中用作除锈剂。与保险粉配制漂毛助剂，羊毛脱脂剂。植物纤维漂白、印染和精漂时的助剂。用于合成洗涤剂作助洗剂。在生产牙膏用磷酸氢钙时加入适量的焦磷酸钠使形成胶体，起稳定作用。化工生产中用作分散剂和乳化剂。水处理中作软水剂，锅炉除垢剂。是生产其他焦磷酸盐的原料。
【用途三】
用于罐头、果汁饮料、奶制品、豆乳等，作品质改良剂。通常多与其他缩合磷酸盐配成制剂使用。
【用途四】
作品质改良剂，有提高食品的络合金属离子、pH值、增加离子强度等的作用，由此改善食品的结着力和持水性。我国规定可用于乳制品、禽鱼制品、肉制品、冰淇淋和方便面，最大使用量5.0g/kg；在罐头、果汁(味)饮料类和植物蛋白饮料中最大使用量为1.0g/kg。作增白剂用于复配薯类淀粉，最大使用量0.025g/kg。

无水焦磷酸钠名称

[ CAS 号 ]:
7722-88-5

[ 中文名 ]:
焦磷酸钠,无水

[ 英文名 ]:
Tetrasodium pyrophosphate

[中文别名 ]:

[英文别名 ]:

Sodium pyrophosphate, anhydrous, tech.
EINECS 231-767-1
MFCD00003513
Tetrasodium diphosphate
Tetrasodium pyrophosphate

无水焦磷酸钠物理化学性质

[ 密度 ]:
2.53 g/mL at 25 °C(lit.)

[ 沸点 ]:
93.8 °C

[ 熔点 ]:
80 °C

[ 分子式 ]:
Na₄O₇P₂

[ 分子量 ]:
265.902

[ 精确质量 ]:
265.871002

[ PSA ]:
155.23000

[ LogP ]:
0.94120

[ 外观性状 ]:
白色结晶粉末或无色晶体

[ 储存条件 ]:
室温

[ 稳定性 ]:
Stable. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
H2O: 0.1 M at 20 °C, clear, colorless

无水焦磷酸钠MSDS

详细MSDS(安全技术说明书)

无水焦磷酸钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UX7350000

CHEMICAL NAME :: Pyrophosphoric acid, tetrasodium salt

CAS REGISTRY NUMBER :: 7722-88-5

LAST UPDATED :: 199712

DATA ITEMS CITED :: 24

MOLECULAR FORMULA :: O7-P2.4Na

MOLECULAR WEIGHT :: 265.90

WISWESSER LINE NOTATION :: NA4 P2-O7

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 7,172,1957

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 59 mg/kg

TOXIC EFFECTS :: Behavioral - excitement Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 108,117,1953

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 7,172,1957

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2980 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 7,445,1957

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 7,445,1957

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 69 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 7,445,1957

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >300 mg/kg

REFERENCE :: ATDAEI Acute Toxicity Data. Journal of the American College of Toxicology, Part B. (Mary Ann Liebert, Inc., 1651 Third Ave., New York, NY 10128) V.1- 1990- Volume(issue)/page/year: 1,47,1990 *** REVIEWS *** ACGIH TLV-TWA 5 mg/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 TOXICOLOGY REVIEW ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 7,24,1957 *** U.S. STANDARDS AND REGULATIONS *** EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION FEREAC Federal Register. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year: 54,7740,1989 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 5 mg/m3 JAN 1993 OEL-BELGIUM:TWA 5 mg/m3 JAN 1993 OEL-DENMARK:TWA 5 mg/m3 JAN 1993 OEL-FINLAND:TWA 5 mg/m3 JAN 1993 OEL-FRANCE:TWA 5 mg/m3 JAN 1993 OEL-SWITZERLAND:TWA 5 mg/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 5 mg/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO TETRASODIUM PYROPHOSPHATE-air:10H TWA 5 mg/m3 REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80224 No. of Facilities: 22297 (estimated) No. of Industries: 179 No. of Occupations: 108 No. of Employees: 177064 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80224 No. of Facilities: 31059 (estimated) No. of Industries: 223 No. of Occupations: 144 No. of Employees: 566370 (estimated) No. of Female Employees: 244801 (estimated)

无水焦磷酸钠安全信息

[ 符号 ]:

GHS05, GHS07

[ 信号词 ]:
Danger

[ 危害声明 ]:
H302-H318

[ 警示性声明 ]:
P280-P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
UX7350000

[ 海关编码 ]:
2835399000

无水焦磷酸钠制备

1.干燥聚合两步法将纯碱加入中和器，在搅拌下加热溶解，加入磷酸进行中和反应生成磷酸氢二钠。控制反应终点Ph 8.2～8.6，反应后溶液的浓度须不低于40°Bé(相对密度1.383)。进行脱色过滤。将磷酸氢二钠溶液浓缩到48°Bé(相对密度1.498)。送到刮片机制成无水磷酸氢二钠薄片。将磷酸氢二钠薄片送到箱式聚合炉中加热聚合，控制物料温度在160～240℃之间。聚合完全的焦磷酸钠经冷却后粉碎，一般通过60目筛，制得无水焦磷酸钠成品。
在两步法生产无水焦磷酸钠的工艺中，可以将磷酸氢二钠的干燥设备改为喷雾干燥塔，将聚合设备改为回转聚合炉，则更适合于大规模的连续化生产。其

2.干燥聚合一步法用高温气体从沸腾聚合炉的下部通入，通过筛板进入炉腔的固定料层，料层由干燥后初步煅烧聚合的磷酸氢二钠固体颗粒组成。物料在此进一步加热聚合，生成焦磷酸钠成品，连续地从筛板上部出料口排出。加热气体继续上行，通过炉腔的沸腾层。被初步干燥的磷酸氢二钠，与还未干燥的磷酸氢二钠在此上下浮动，发生混合、干燥、聚合等几个过程，制得无水焦磷酸钠成品。
尾气夹带部分小粒固体物料从炉顶排出，尾气经旋风分离器处理，收集下部分固体物料，返回沸腾层。其
3.将磷酸氢二钠加热至500℃，脱水5h，可得到纯度在98％以上的焦磷酸钠。精制法是在水溶液中反复重结晶后，在铂坩埚中于500℃以上煅烧2～3h可得无水物。

无水焦磷酸钠海关

[ 海关编码 ]: 2835399000

无水焦磷酸钠文献

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.

Drug Des. Devel. Ther. 9 , 1627-52, (2015)

Alisertib (ALS) is an investigational potent Aurora A kinase inhibitor currently undergoing clinical trials for the treatment of hematological and non-hematological malignancies. However, its antitumo...

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.

Drug Des. Devel. Ther. 9 , 1555-84, (2015)

Osteosarcoma (OS) is the most common malignant bone tumor occurring mostly in children and adolescents between 10 and 20 years of age with poor response to current therapeutics. Alisertib (ALS, MLN823...

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.

Drug Des. Devel. Ther. 9 , 425-64, (2015)

Ovarian cancer is a leading killer of women, and no cure for advanced ovarian cancer is available. Alisertib (ALS), a selective Aurora kinase A (AURKA) inhibitor, has shown potent anticancer effects, ...

更多文献